Survival Outcomes Associated With Prolonged Pembrolizumab After Definitive Chemoradiation for Non-small Cell Lung Cancer.

Homeniuk A, Syed A, Atrash A

Open source

DOI
10.1016/j.clon.2026.104227
Published
2026 Sep
Container
Clinical oncology (Royal College of Radiologists (Great Britain))
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.clon.2026.104227,
  title = {Survival Outcomes Associated With Prolonged Pembrolizumab After Definitive Chemoradiation for Non-small Cell Lung Cancer.},
  author = {Homeniuk A and Syed A and Atrash A},
  year = {2026},
  journal = {Clinical oncology (Royal College of Radiologists (Great Britain))},
  doi = {10.1016/j.clon.2026.104227},
  url = {https://doi.org/10.1016/j.clon.2026.104227}
}

RIS

TY  - JOUR
TI  - Survival Outcomes Associated With Prolonged Pembrolizumab After Definitive Chemoradiation for Non-small Cell Lung Cancer.
AU  - Homeniuk A
AU  - Syed A
AU  - Atrash A
PY  - 2026
JO  - Clinical oncology (Royal College of Radiologists (Great Britain))
DO  - 10.1016/j.clon.2026.104227
UR  - https://doi.org/10.1016/j.clon.2026.104227
ER  - 

APA

A, H., A, S., & A, A. (2026). Survival Outcomes Associated With Prolonged Pembrolizumab After Definitive Chemoradiation for Non-small Cell Lung Cancer.. Clinical oncology (Royal College of Radiologists (Great Britain)). https://doi.org/10.1016/j.clon.2026.104227

Source records